Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 331 to 345 of 676 results for diabetes

  1. Depression in adults with a chronic physical health problem: recognition and management (CG91)

    This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.

    Clinical guideline
    Published
    28 October 2009
    View recommendations

    Sections for CG91

  2. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

    Technology appraisal guidance
    Last updated
    1 May 2025
    View recommendations

    Sections for TA878

  3. Methotrexate and risk of hepatotoxicity:- What is the impact of methotrexate compared with other approaches to care (for example other systemic non-biological or biological treatments) on risk of significant liver disease in people with psoriasis and do risk factors such as obesity, alcohol use or diabetes alter this risk?

    people with psoriasis and do risk factors such as obesity, alcohol use or diabetes alter this risk? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    9 June 2015

  4. Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

    Evidence-based recommendations on myocardial perfusion scintigraphy for diagnosing and managing angina and myocardial infarction in adults.

    Technology appraisal guidance
    Last updated
    1 July 2011
    View recommendations

    Sections for TA73

  5. Physical health of people in prisons (QS156)

    This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    7 September 2017
    View quality statements

    Sections for QS156

  6. Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

    Discontinued Reference number: GID-TA10177

    Technology appraisal guidance
    Discontinued

  7. Ticagrelor for the treatment of acute coronary syndromes (TA236)

    Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.

    Technology appraisal guidance
    Published
    26 October 2011
    View recommendations

    Sections for TA236

  8. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

    Technology appraisal guidance
    Last updated
    2 July 2021
    View recommendations

    Sections for TA275

  9. Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

    Discontinued Reference number: GID-TA10375

    Technology appraisal guidance
    Discontinued

  10. Practitioners and providers' awareness of risk in black, Asian and other minority ethnic groups: Are clinicians, practitioners and weight management service providers aware that black, Asian and other minority ethnic groups are at the same risk of type 2 diabetes and mortality at a lower BMI compared with the white population. If so, do they intervene at lower BMI and waist-to-height ratio thresholds?

    Asian and other minority ethnic groups are at the same risk of type 2 diabetes and mortality at a lower BMI compared with the white...

    Research recommendation
    Published
    30 September 2022

  11. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued Reference number: GID-TA10429

    Technology appraisal guidance
    Discontinued

  12. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

    Technology appraisal guidance
    Last updated
    2 July 2021
    View recommendations

    Sections for TA249

  13. Laparoscopic gastric plication for the treatment of severe obesity (IPG432)

    Evidence-based recommendations on laparoscopic gastric plication for the treatment of morbid obesity. This involves folding the stomach in on itself and stitching it together to reduce its volume.

    Interventional procedures guidance
    Published
    27 November 2012
    View recommendations

    Sections for IPG432

  14. Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)

    Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.

    HealthTech guidance
    Published
    19 June 2025
    View recommendations

    Sections for HTG751

  15. Research is recommended to address uncertainties in the potential benefits to patients and the NHS of using VibraTip. Research is needed into the diagnostic accuracy of VibraTip compared with the 10 g monofilament and calibrated tuning fork in the diagnosis of peripheral neuropathy in people with diabetes. This research should also address the assessment of vibration perception compared with touch sensation in this clinical context.

    calibrated tuning fork in the diagnosis of peripheral neuropathy in people with diabetes. This research should also address the...

    Research recommendation
    Published
    9 June 2015